Trulance

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced an offering of 21 million shares of its common stock at $2.58 per share in November, and at least one Wall Street analyst said another dilutive offering is imminent. The Analyst Oppenheimer's Derek Archila downgraded Synergy...

Cantor Fitzgerald initiated coverage of Synergy Pharmaceuticals Inc (NASDAQ: SGYP) at Overweight with a price target of $11. Analyst William Tanner estimates second quarter earnings of $1.4 million with a negative $0.25 EPS. Fiscal 2017 earnings are estimated to be $11.3 million. Opportunities In...

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) presented positive results from its Phase 3 study of plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C). In two large studies, Synergy examined plecanatide, marketed as "Trulance," in both 3 mg and 6 mg doses....

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced last week it has been issued three new patents from the U.S. Patent and Trademark Office. The first patent relates to the manufacturing method for TRULANCE (plecanatide) and the other two relate to formulations and methods of using Trulance for...

Canaccord Genuity said it views Takeda Pharmaceutical Co Ltd (ADR) (OTC: TKPYY)’s speculated interest in buying Synergy Pharmaceuticals Inc (NASDAQ: SGYP) as a positive step. The potential deal could boost its GI (gastrointestine) portfolio. Speculative Interest Commenting on the indication...

After market close on January 19, Synergy Pharmaceuticals Inc (NASDAQ: SGYP) reported that it had achieved FDA approval for its lead drug, plecanatide, in constipation-predominant irritable bowel syndrome (IBS-C). Rodman & Renshaw’s Raghuram Selvaraju reiterated a Buy rating on the...

The U.S. Food and Drug Administration said it approved Synergy Pharmaceuticals Inc's (NASDAQ: SGYP) plecanatide, branded as Trulance, for the treatment of chronic idiopathic constipation (CIC). This approval marks the company’s first. Trulance is a one-tablet-a-day drug used to treat...